Cochlear Ltd (Cochlear) manufactures and markets implantable hearing devices for patients suffering from hearing loss and develops integrated hearing solutions. Its major products include cochlear implant systems for patients with moderate to profound sensorineural hearing loss; bone conduction systems for patients with conductive hearing loss, mixed hearing loss or single-sided deafness; and acoustic implants for patients with moderate to severe sensorineural or mixed hearing loss.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Cochlear has made significant progress on major projects with focus on implant innovations aimed at enhancing auditory nerve stimulation quality. Its efforts include developing drug-eluting electrodes and fully implantable cochlear implants. It is collaborating with leading institutions such as the University of Melbourne, Royal Victorian Eye and Ear Hospital, Macquarie University, Australian Hearing Hub, Johns Hopkins University, and the Cochlear Center for Hearing and Public Health. The company’s research spans various areas including novel surgical techniques, advanced electrodes, objective measures, sound coding, audiology, and aftercare. Cochlear holds a portfolio of over 2,300 patents and patent applications worldwide. It operates a global innovation network with more than 600 R&D employees spread across various facilities. Primary R&D activities are based at the Australian Hearing Hub in Sydney, while the advanced innovation hub is at the Cochlear Technology Center in Belgium. The company also operates an acoustics and software hub in Sweden, hosts the Oticon Medical team in France, and is in the process of expanding its R&D capabilities in Malaysia. In FY2025, the company spent AUD291.5 million on its R&D activities, which as a percentage of revenue stood at 12.4% and grew 5.2% YoY.